Pyridorin in type 2 diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 23, Issue 1, 2012, Pages 131-136

  Lewis, Edmund J ^a,h   Greene, Tom ^b   Spitalewiz, Samuel ^c   Blumenthal, Samuel ^d   Berl, Tomas ^e   Hunsicker, Lawrence G ^f   Pohl, Marc A ^g   Rohde, Richard D ^h   Raz, Itamar ⁱ   Yerushalmy, Yair ^j   Yagil, Yoram ^k   Herskovits, Tommy ^l   Atkins, Robert C ^m   Reutens, Anne T ^m   Packham, David K ⁿ   Lewis, Julia B ^o  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h Collaborative Study Group ^*  (United States)

ⁱ HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^j RABIN MEDICAL CENTER   (Israel)

^k BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^l Institution of Diabetes and Metabolism   (Israel)

^m MONASH UNIVERSITY   (Australia)

ⁿ ROYAL MELBOURNE HOSPITAL   (Australia)

^o VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PLACEBO; PROTEIN; PYRIDORIN; PYRIDOXAMINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84863393388     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011030272     Document Type: Article

References (23)

1. US Renal Data System: USRS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009
2. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl JMed 345: 851-860, 2001
3. Centers for Disease Control and Prevention: Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes-United States and Puerto Rico, 1996-2007. MMWR Morb Mortal Wkly Rep 2010;59:1361-1366.
4. Chetyrkin SV, Mathis ME, Ham AJ, Hachey DL, Hudson BG, Voziyan PA: Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: inhibition by pyridoxamine. Free Radic Biol Med 44: 1276-1285, 2008 (Pubitemid 351410549)
5. Voziyan PA, Metz TO, Baynes JW, Hudson BG: A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 277: 3397-3403, 2002 (Pubitemid 34953208)
6. Chetyrkin SV, Zhang W, Hudson BG, Serianni AS, Voziyan PA: Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine. Biochemistry 47: 997-1006, 2008
7. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW: Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions.Mechanism of action of pyridoxamine. J Biol Chem 275: 21177-21184, 2000 (Pubitemid 30481811)
8. Booth AA, Khalifah RG, Todd P, Hudson BG: In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem 272: 5430-5437, 1997 (Pubitemid 27102361)
9. Voziyan PA, Khalifah RG, Thibaudeau C, Yildiz A, Jacob J, Serianni AS, Hudson BG: Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redoxmetal ions. J Biol Chem278: 46616-46624, 2003 (Pubitemid 37452237)
10. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61: 939-950, 2002 (Pubitemid 34175462)
11. Alderson NL, Chachich ME, Frizzell N, Canning P, Metz TO, Januszewski AS, Youssef NN, Stitt AW, Baynes JW, Thorpe SR: Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia 47: 1385-1395, 2004 (Pubitemid 39232424)
12. Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, Baynes JW: The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 63: 2123-2133, 2003 (Pubitemid 36605823)
13. Zheng F, Zeng YJ, Plati AR, Elliot SJ, Berho M, Potier M, Striker LJ, Striker GE: Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/dbmice. Kidney Int 70: 507-514, 2006 (Pubitemid 44141577)
14. Tanimoto M, Gohda T, Kaneko S, Hagiwara S, Murakoshi M, Aoki T, Yamada K, Ito T, Matsumoto M, Horikoshi S, Tomino Y: Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 56: 160-167, 2007 (Pubitemid 46074060)
15. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB: Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 27: 605-614, 2007 (Pubitemid 350014947)
16. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth JP; ACTION I Investigator Group: Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24: 32-40, 2004 (Pubitemid 38250484)
17. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74: 1143-1155, 1984 (Pubitemid 15210185)
18. Østerby R, Gall M-A, Schmitz A,Nielsen FS, Nyberg G, Parving H-H: Glomerular structure and function in proteinuric type 2 (noninsulin- dependent) diabetic patients. Diabetologia 36: 1064-1070, 1993 (Pubitemid 23288777)
19. Schwartz MM, Lewis EJ, Leonard-Martin T, Lewis JB, Batlle D; The Collaborative Study Group: Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. Nephrol Dial Transplant 13: 2547-2552, 1998 (Pubitemid 28445867)
20. White KE, Bilous RW: Type 2 diabetic patients with nephropathy show structural-functionalrelationships that are similar to type 1 disease. J Am Soc Nephrol 11: 1667-1673, 2000
21. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46: 223-234, 1995
22. Khalifah RG, Baynes JW, Hudson BG: Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 257: 251-258, 1999 (Pubitemid 29301430)
23. Kang Z, LiH, LiG, Yin D: Reaction of pyridoxamine withmalondialdehyde: mechanism of inhibition of formation of advanced lipoxidation endproducts. Amino Acids 30: 35-61, 2006